Modafinil for Atypical Depression: Effects of Open-Label and Double-Blind Discontinuation Treatment

Tomas Thorne

Basic

Last Updated: February 20, 2023

Modafinil for Atypical Depression

Research Based

ResearchPeptides.org follows the strictest sourcing guidelines in the health and nootropics industry. Our focus is to exclusively link to peer-reviewed studies found on respected websites, like PubMed. We focus on finding the most accurate information from the scientific source.

Our goal is to provide you with the most scientifically accurate, unbiased, and comprehensive information regarding all research peptides and SARMs.

All of our content is written by people with a strong science background, including medical researchers.

Our content is continually monitored by an internal peer-review process to ensure accuracy. We strive to never have a piece of inaccurate information on this website.

If you feel that any of our content is inaccurate or out-of-date, please contact us at: [email protected]

ABSTRACT

Atypical depression, with features of hypersomnia, hyperphagia, anergia, and rejection sensitivity, is a common presentation of major depressive disorder. There are few available effective therapies for this disorder. We test modafinil, a novel wake-promoting agent, as monotherapy for atypical depression in a double-blind, placebo-controlled, relapse prevention trial after open-label treatment.

We found that modafinil significantly improved atypical depression symptoms during 12 weeks of open-label treatment (mean +/- SD Hamilton Depression Scale (29-item version) score changed from 34 +/- 8.2 at baseline to 9.7 +/- 9.3, P < 0.0001), and that benefits were maintained alike in both the continuation and placebo arms during the double-blind treatment phase (P = 0.92). Modafinil was well tolerated and the drug was associated with significant weight loss compared with placebo (P = 0.01).

References

Table of Contents
    Add a header to begin generating the table of contents